- Home
- ZNTL vs EDIT Comparison
ZNTL vs EDIT Comparison
Compare ZNTL & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | EDIT |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.9M | 310.9M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | EDIT |
|---|---|---|
| Price | $4.06 | $2.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $6.60 | $5.30 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.03 | ★ 37.50 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $1.13 | $1.56 |
| 52 Week High | $6.95 | $4.54 |
Technical Indicators
Market Signals| Indicator | ZNTL | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 51.88 | 47.37 |
| Support Level | $3.75 | $2.42 |
| Resistance Level | $4.40 | $3.27 |
| Average True Range (ATR) | 0.32 | 0.19 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 59.20 | 40.00 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.